Text Size
Santen Global

2010 Press Release

RSS

Press Release

Santen Launches DIQUAS Ophthalmic Solution 3% for Dry Eye Treatment in Japan
Santen Announces Financial Results for the Year ended March 31, 2009
Santen Announces Financial Result for the Second Quarter ended September 30, 2010
Reorganization of manufacturing function and transfer of Osaka plant
Santen Announces Financial Result for the First Quarter ended June 30, 2010
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Banyu and Santen Launch COSOPT® Combination Ophthalmic Solution: Glaucoma and Ocular Hypertension Drug
Renewal of the Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
IR News Notice of the Change of Representative Director and the Nominations for the Members of the Board of Directors
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
Santen Launches Glaucoma and Ocular Hypertension Treatment TAFLOTAN® in Korea
Clinical Data, Inc. Licenses Adenosine A2A Agonist to Santen for Development of Ophthalmic Treatments
Santen Announces Approval of DIQUAS for Dry Eye Treatment in Japan
MHLW Grants Approval for COSOPT Combination Ophthalmic Solution
Change of management positions at Santen Inc.
Notice of the appointment of Corporate Officers
Santen Files Manufacturing/Marketing Approval of its Broad Spectrum Anti-Infective Ophthalmic Solution DE-108 (Generic name: Levofloxacin, high concentration)
Banyu and Santen Announce Co-Promotion Agreement for Combination Ophthalmic Solution, Treatment for Glaucoma and Ocular Hypertension
Santen Announces Financial Result for the Third Quarter ended December 31, 2009
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved